TY - JOUR
T1 - Global burden of acute lower respiratory infection associated with human metapneumovirus in children under 5 years in 2018
T2 - a systematic review and modelling study
AU - Respiratory Virus Global Epidemiology Network
AU - Wang, Xin
AU - Li, You
AU - Deloria-Knoll, Maria
AU - Madhi, Shabir A.
AU - Cohen, Cheryl
AU - Ali, Asad
AU - Basnet, Sudha
AU - Bassat, Quique
AU - Brooks, W. Abdullah
AU - Chittaganpitch, Malinee
AU - Echavarria, Marcela
AU - Fasce, Rodrigo A.
AU - Goswami, Doli
AU - Hirve, Siddhivinayak
AU - Homaira, Nusrat
AU - Howie, Stephen R.C.
AU - Kotloff, Karen L.
AU - Khuri-Bulos, Najwa
AU - Krishnan, Anand
AU - Lucero, Marilla G.
AU - Lupisan, Socorro
AU - Mira-Iglesias, Ainara
AU - Moore, David P.
AU - Moraleda, Cinta
AU - Nunes, Marta
AU - Oshitani, Histoshi
AU - Owor, Betty E.
AU - Polack, Fernando P.
AU - O'Brien, Katherine L.
AU - Rasmussen, Zeba A.
AU - Rath, Barbara A.
AU - Salimi, Vahid
AU - Scott, J. Anthony G.
AU - Simões, Eric A.F.
AU - Strand, Tor A.
AU - Thea, Donald M.
AU - Treurnicht, Florette K.
AU - Vaccari, Linda C.
AU - Yoshida, Lay Myint
AU - Zar, Heather J.
AU - Campbell, Harry
AU - Nair, Harish
AU - Libster, Romina
AU - Otieno, Grieven
AU - Joundi, Imane
AU - Broor, Shobha
AU - Nicol, Mark
AU - Amarchand, Ritvik
AU - Shi, Ting
AU - López-Labrador, F. Xavier
N1 - Funding Information:
This study was funded by the Bill & Melinda Gates Foundation (OPP 1172551). HN and HC are members of the Respiratory Syncytial Virus Consortium in Europe, which has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (116019) that receives support from the EU Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations. The community-based paediatric acute respiratory infection study in central Vietnam was supported by the Japan Initiate for Global Research Network on Infectious Diseases from the Ministry of Education, Culture, Sport, Science & Technology in Japan, and Japan Agency for Medical Research and Development (JP18fm0108001). XW and YL were supported by scholarships from the China Scholarship Council during the conduct of this study. We thank Javier Diez-Domingo, Sozinho Acacio, Leilani T Nillos, Andrea Gutierrez, and Noelia Reyes for their contributions to study design and the analysis of primary data for the included studies. The findings and conclusions in this Article are those of the authors and do not necessarily represent the official position of the National Institutes of Health or US Department of Health and Human Services.
Funding Information:
This study was funded by the Bill & Melinda Gates Foundation (OPP 1172551). HN and HC are members of the Respiratory Syncytial Virus Consortium in Europe, which has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (116019) that receives support from the EU Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations. The community-based paediatric acute respiratory infection study in central Vietnam was supported by the Japan Initiate for Global Research Network on Infectious Diseases from the Ministry of Education, Culture, Sport, Science & Technology in Japan, and Japan Agency for Medical Research and Development (JP18fm0108001). XW and YL were supported by scholarships from the China Scholarship Council during the conduct of this study. We thank Javier Diez-Domingo, Sozinho Acacio, Leilani T Nillos, Andrea Gutierrez, and Noelia Reyes for their contributions to study design and the analysis of primary data for the included studies. The findings and conclusions in this Article are those of the authors and do not necessarily represent the official position of the National Institutes of Health or US Department of Health and Human Services.
Publisher Copyright:
© 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license
PY - 2021/1
Y1 - 2021/1
N2 - Background: Human metapneumovirus is a common virus associated with acute lower respiratory infections (ALRIs) in children. No global burden estimates are available for ALRIs associated with human metapneumovirus in children, and no licensed vaccines or drugs exist for human metapneumovirus infections. We aimed to estimate the age-stratified human metapneumovirus-associated ALRI global incidence, hospital admissions, and mortality burden in children younger than 5 years. Methods: We estimated the global burden of human metapneumovirus-associated ALRIs in children younger than 5 years from a systematic review of 119 studies published between Jan 1, 2001, and Dec 31, 2019, and a further 40 high quality unpublished studies. We assessed risk of bias using a modified Newcastle-Ottawa Scale. We estimated incidence, hospital admission rates, and in-hospital case-fatality ratios (hCFRs) of human metapneumovirus-associated ALRI using a generalised linear mixed model. We applied incidence and hospital admission rates of human metapneumovirus–associated ALRI to population estimates to yield the morbidity burden estimates by age bands and World Bank income levels. We also estimated human metapneumovirus-associated ALRI in-hospital deaths and overall human metapneumovirus-associated ALRI deaths (both in-hospital and non-hospital deaths). Additionally, we estimated human metapneumovirus-attributable ALRI cases, hospital admissions, and deaths by combining human metapneumovirus-associated burden estimates and attributable fractions of human metapneumovirus in laboratory-confirmed human metapneumovirus cases and deaths. Findings: In 2018, among children younger than 5 years globally, there were an estimated 14·2 million human metapneumovirus-associated ALRI cases (uncertainty range [UR] 10·2 million to 20·1 million), 643 000 human metapneumovirus-associated hospital admissions (UR 425 000 to 977 000), 7700 human metapneumovirus-associated in-hospital deaths (2600 to 48 800), and 16 100 overall (hospital and community) human metapneumovirus-associated ALRI deaths (5700 to 88 000). An estimated 11·1 million ALRI cases (UR 8·0 million to 15·7 million), 502 000 ALRI hospital admissions (UR 332 000 to 762 000), and 11 300 ALRI deaths (4000 to 61 600) could be causally attributed to human metapneumovirus in 2018. Around 58% of the hospital admissions were in infants under 12 months, and 64% of in-hospital deaths occurred in infants younger than 6 months, of which 79% occurred in low-income and lower-middle-income countries. Interpretation: Infants younger than 1 year have disproportionately high risks of severe human metapneumovirus infections across all World Bank income regions and all child mortality settings, similar to respiratory syncytial virus and influenza virus. Infants younger than 6 months in low-income and lower-middle-income countries are at greater risk of death from human metapneumovirus-associated ALRI than older children and those in upper-middle-income and high-income countries. Our mortality estimates demonstrate the importance of intervention strategies for infants across all settings, and warrant continued efforts to improve the outcome of human metapneumovirus-associated ALRI among young infants in low-income and lower-middle-income countries. Funding: Bill & Melinda Gates Foundation.
AB - Background: Human metapneumovirus is a common virus associated with acute lower respiratory infections (ALRIs) in children. No global burden estimates are available for ALRIs associated with human metapneumovirus in children, and no licensed vaccines or drugs exist for human metapneumovirus infections. We aimed to estimate the age-stratified human metapneumovirus-associated ALRI global incidence, hospital admissions, and mortality burden in children younger than 5 years. Methods: We estimated the global burden of human metapneumovirus-associated ALRIs in children younger than 5 years from a systematic review of 119 studies published between Jan 1, 2001, and Dec 31, 2019, and a further 40 high quality unpublished studies. We assessed risk of bias using a modified Newcastle-Ottawa Scale. We estimated incidence, hospital admission rates, and in-hospital case-fatality ratios (hCFRs) of human metapneumovirus-associated ALRI using a generalised linear mixed model. We applied incidence and hospital admission rates of human metapneumovirus–associated ALRI to population estimates to yield the morbidity burden estimates by age bands and World Bank income levels. We also estimated human metapneumovirus-associated ALRI in-hospital deaths and overall human metapneumovirus-associated ALRI deaths (both in-hospital and non-hospital deaths). Additionally, we estimated human metapneumovirus-attributable ALRI cases, hospital admissions, and deaths by combining human metapneumovirus-associated burden estimates and attributable fractions of human metapneumovirus in laboratory-confirmed human metapneumovirus cases and deaths. Findings: In 2018, among children younger than 5 years globally, there were an estimated 14·2 million human metapneumovirus-associated ALRI cases (uncertainty range [UR] 10·2 million to 20·1 million), 643 000 human metapneumovirus-associated hospital admissions (UR 425 000 to 977 000), 7700 human metapneumovirus-associated in-hospital deaths (2600 to 48 800), and 16 100 overall (hospital and community) human metapneumovirus-associated ALRI deaths (5700 to 88 000). An estimated 11·1 million ALRI cases (UR 8·0 million to 15·7 million), 502 000 ALRI hospital admissions (UR 332 000 to 762 000), and 11 300 ALRI deaths (4000 to 61 600) could be causally attributed to human metapneumovirus in 2018. Around 58% of the hospital admissions were in infants under 12 months, and 64% of in-hospital deaths occurred in infants younger than 6 months, of which 79% occurred in low-income and lower-middle-income countries. Interpretation: Infants younger than 1 year have disproportionately high risks of severe human metapneumovirus infections across all World Bank income regions and all child mortality settings, similar to respiratory syncytial virus and influenza virus. Infants younger than 6 months in low-income and lower-middle-income countries are at greater risk of death from human metapneumovirus-associated ALRI than older children and those in upper-middle-income and high-income countries. Our mortality estimates demonstrate the importance of intervention strategies for infants across all settings, and warrant continued efforts to improve the outcome of human metapneumovirus-associated ALRI among young infants in low-income and lower-middle-income countries. Funding: Bill & Melinda Gates Foundation.
UR - http://www.scopus.com/inward/record.url?scp=85098200463&partnerID=8YFLogxK
U2 - 10.1016/S2214-109X(20)30393-4
DO - 10.1016/S2214-109X(20)30393-4
M3 - Article
C2 - 33248481
AN - SCOPUS:85098200463
SN - 2214-109X
VL - 9
SP - e33-e43
JO - The Lancet Global Health
JF - The Lancet Global Health
IS - 1
ER -